Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Accepted for publication November 13, 2015
- Published online March 1, 2016.
Article Versions
- Latest version (February 1, 2016 - 04:00).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2016 Free online via JRheum Full Release option
Author Information
- Yoshiya Tanaka,
- Kahaku Emoto⇑,
- Zhihong Cai,
- Takehiro Aoki,
- Douglas Schlichting,
- Terence Rooney and
- William Macias
- From the First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu; Eli Lilly and Co., Tokyo; Eli Lilly Japan K.K., Kobe, Japan; Eli Lilly and Co., Indianapolis, Indiana, USA.
- Sponsored by Eli Lilly Japan K.K. and Eli Lilly and Co., manufacturer/licensee of baricitinib. Eli Lilly Japan K.K. and Eli Lilly and Co. were involved in the study design, data collection, data analysis, and preparation of the manuscript. Medical writing assistance was provided by Janelle Keys, PhD, CMPP, and Rebecca Lew, PhD, CMPP, of ProScribe, part of the Envision Pharma Group, and was funded by Eli Lilly Japan K.K. ProScribe’s services complied with international guidelines for Good Publication Practice (GPP2). ZC and TA are employees of Eli Lilly Japan K.K. KE, DS, TR, and WM are employees of Eli Lilly and Co. and KE owns stock in the company.
- Y. Tanaka, MD, PhD, Professor, First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health; K. Emoto, MD, PhD, Medical Advisor, Eli Lilly and Co.; Z. Cai, PhD, Senior Associate, Eli Lilly Japan K.K.; T. Aoki, PhD, Senior Associate, Eli Lilly Japan K.K.; D. Schlichting, RN, MS, Principal Research Scientist, Eli Lilly and Co.; T. Rooney, MD, Medical Director, Eli Lilly and Co.; W. Macias, MD, PhD, Distinguished Medical Fellow, Eli Lilly and Co.
- Address correspondence to Dr. K. Emoto, Eli Lilly and Co., Akasaka, Minato-ku, Tokyo, 107-0052, Japan. E-mail: emoto_kahaku{at}lilly.com